Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

Stangier J, Clemens A.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S. doi: 10.1177/1076029609343004. Epub 2009 Aug 19. Review.

PMID:
19696042
2.

Dabigatran etexilate: future directions in anticoagulant treatment.

Schulman S, Reilly PA.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:32S-41S. doi: 10.1177/1076029609344199. Epub 2009 Aug 13. Review.

PMID:
19679590
3.
4.

Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.

Dahl OE.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:17S-24S. doi: 10.1177/1076029609344588. Epub 2009 Aug 19. Review.

PMID:
19696041
5.

Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.

Eriksson BI, Friedman RJ.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:25S-31S. doi: 10.1177/1076029609340668. Epub 2009 Jul 31. Review.

PMID:
19648146
6.

Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.

Garza R, Huo MH.

Expert Rev Cardiovasc Ther. 2012 Apr;10(4):423-7. doi: 10.1586/erc.12.15. Review.

PMID:
22458575
7.

New options with dabigatran etexilate in anticoagulant therapy.

Maegdefessel L, Spin JM, Azuma J, Tsao PS.

Vasc Health Risk Manag. 2010 May 25;6:339-49. Review.

8.

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Review.

PMID:
21817082
9.

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J.

Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29. Review.

10.

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A.

Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Review.

PMID:
20352166
11.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
12.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
14.

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

Ma TK, Yan BP, Lam YY.

Pharmacol Ther. 2011 Feb;129(2):185-94. doi: 10.1016/j.pharmthera.2010.09.005. Epub 2010 Oct 12. Review.

PMID:
20920530
15.

Dabigatran etexilate in venous thromboembolism.

Ferrer E.

Drugs Today (Barc). 2009 Oct;45(10):715-24. doi: 1396674/dot.2009.45.10.1425728. Review.

PMID:
20069135
16.
17.

Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.

Wilcox R, Pendleton RC, Smock KJ, Rodgers GM.

Hosp Pract (1995). 2011 Aug;39(3):23-34. doi: 10.3810/hp.2011.08.576. Review.

PMID:
21881389
18.

Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery.

Wolowacz SE.

Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):9-25. doi: 10.1586/erp.10.89. Review.

PMID:
21351853
19.

Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?

Guay DR.

Hosp Pract (1995). 2011 Feb;39(1):105-25. doi: 10.3810/hp.2011.02.381. Review.

PMID:
21441766
20.

Implications of new anticoagulants in primary practice.

Perez A, Eraso LH, Merli GJ.

Int J Clin Pract. 2013 Feb;67(2):139-56. doi: 10.1111/ijcp.12023. Review. Erratum in: Int J Clin Pract. 2013 Aug;67(8):816. Dosage error in article text.

PMID:
23305476
Items per page

Supplemental Content

Write to the Help Desk